Literature DB >> 1918036

Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart.

A Kinoshita1, H Urata, F M Bumpus, A Husain.   

Abstract

Human heart chymase, a chymotrypsin-like serine proteinase that hydrolyzes the Phe8-His9 bond in angiotensin I (Ang I) to yield the octapeptide hormone angiotensin II (Ang II) and His-Leu, is the most specific, efficient Ang II-forming enzyme described. Other mammalian chymases display a much broader substrate specificity. To better define its substrate specificity, we have mapped the extended substrate-binding site of human heart chymase using Ang I analogs. The enzyme has a preference for aromatic amino acids phenylalanine, tyrosine, and tryptophan at the P1 site. At the S2 subsite there is a significant preference for proline over hydrophobic or hydrophilic amino acids. There is no clear preference for hydrophobic or hydrophilic amino acids at the S'1 and S'2 subsites, but an Ang I analog containing a P'1 proline is not hydrolyzed and one with a P'2 proline is hydrolyzed poorly. An increasing reduction in reactivity occurs when the P position amino acids in Ang I are deleted sequentially from the N terminus. An increase or decrease in the length of the His-Leu leaving group also produces a marked decrease in reactivity. No single determinant in Ang I is preeminently required for efficient catalysis, but several factors acting synergistically appear to be important. Thus, we propose that ideal substrates for human heart chymase should contain the structure nXaa-Pro-[Phe, Tyr, or Trp]-Yaa-Yaa, where n greater than or equal to 6; Xaa = any amino acid; Yaa = any amino acid except proline. This structure exists in Ang I and neurotensin, both of which are good substrates for human heart chymase. These findings indicate that the selection of the scissile bond by the extended substrate-binding site of human heart chymase is more restricted than that in other chymases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918036

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 2.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

3.  Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces.

Authors:  L J Dell'Italia; Q C Meng; E Balcells; C C Wei; R Palmer; G R Hageman; J Durand; G H Hankes; S Oparil
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

4.  Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.

Authors:  H Urata; K D Boehm; A Philip; A Kinoshita; J Gabrovsek; F M Bumpus; A Husain
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 5.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

6.  Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon.

Authors:  B D Hoit; Y Shao; A Kinoshita; M Gabel; A Husain; R A Walsh
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction.

Authors:  R Studer; H Reinecke; B Müller; J Holtz; H Just; H Drexler
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

8.  Chymase mediates angiotensin-(1-12) metabolism in normal human hearts.

Authors:  Sarfaraz Ahmad; Chih-Chang Wei; Jose Tallaj; Louis J Dell'Italia; Norihito Moniwa; Jasmina Varagic; Carlos M Ferrario
Journal:  J Am Soc Hypertens       Date:  2013-01-10

9.  Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

Authors:  W Wienen; N Hauel; J C Van Meel; B Narr; U Ries; M Entzeroth
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

10.  Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature.

Authors:  Sungmi Park; Benjamin J Bivona; Stephen M Ford; Sen Xu; Hiroyuki Kobori; Lawrence de Garavilla; Lisa M Harrison-Bernard
Journal:  Hypertension       Date:  2012-12-03       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.